Transarterial Therapies for Hepatocellular Carcinoma

Liver Cancer. 2016 Nov;6(1):27-33. doi: 10.1159/000449347. Epub 2016 Nov 29.

Abstract

Background: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs.

Summary: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors.

Key messages: Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy.

Keywords: Predictors of response after TAE and TACE for HCC; TAE and TACE for HCC.

Publication types

  • Review